Pune-based Emcure Pharmaceuticals has pulled out its proposed red herring prospectus or DRHP with securities market regulator SEBI. Emcure Pharmaceuticals on Wednesday said it has filed a draft red herring prospectus (DRHP) with the Sebi for launching an initial public offer. Pune-based Emcure Pharmaceuticals has filed draft red herring prospectus ( DRHP) with SEBI for initial public offering that includes fresh issue.
|Published (Last):||3 January 2014|
|PDF File Size:||3.56 Mb|
|ePub File Size:||6.19 Mb|
|Price:||Free* [*Free Regsitration Required]|
These areas include cardiology, pain and analgesics, HIV, gynecology, nephrology, anti-infective, and vitamins, minerals and nutrients. Thu, Dec 19 Your Reason has been Reported to the admin.
Book running lead rmcure to the issue include Bank of America Merrill Lynch. Secondary transactions set the ground for appropriate valuations as there is no information arbitrage unlike in a primary transaction. Private equity major Blackstone has started the process of exiting its maiden investment in India, Emcure Pharmaceuticals.
Never miss a great news story!
Emcure Pharmaceuticals files IPO papers with SEBI –
To see your saved stories, click on link hightlighted emcyre bold. For the nine months ended December 31,Emcure’s revenue from operations was Rs 1, crore with net profit at Rs Pune-based Emcure Pharmaceuticals has filed draft red herring prospectus DRHP with SEBI for initial public offering that includes fresh issue of upto Rs crore and an offer for sale of upto 25,13, equity share.
Emcure becomes the first proposed IPO to be withdrawn after the election results and the fourth since January 1 this year. Find this comment offensive? These areas include cardiology, pain and analgesics, HIV, gynecology, nephrology, anti-infective, and vitamins, minerals and nutrients. The PE firm is selling around 1. Fortis again pushes back date to complete RHT Health deal; auditor resigns. The content may not be copied, broadcast, downloaded and stored in any mediumrdhp, adapted or changed in any way whatsoever without the prior written permission of Mosaic Media Ventures Private Limited.
Here’s how the world is celebrating Christmas. Another pharmaceutical firm which filed for public offering recently was Intas Pharmaceuticals.
Emcure Pharmaceuticals files for IPO; Blackstone to part exit
It has subsidiaries in Brazil, DubaiNigeria, Singapore and South Africa and branch offices in Morocco and Russiawhich play an important role in its international operations, the release said.
The IPO comprises a fresh issue of equity shares aggregating up to Rs crore and an offer for sale of up to 2, equity shares by certain existing shareholders of the company, a statement issued here said. The company is engaged in developing, manufacturing and marketing a broad range of pharmaceutical products globally. Edited by Joby Puthuparampil Johnson. Ltd with returns of almost three times. Link Intime India Private Limited is a registrar to the issue. This will alert our moderators to take action Name Reason for reporting: Pune-based Emcure Pharmaceuticals has pulled out its proposed initial public offer IPO which was to raise around Rs crore besides giving part exit to Blackstone in its maiden investment in India.
This will alert our moderators to take action. Get instant notifications from Economic Times Allow Not now. Of these revenues, The issue also involves a secondary sale 2. Infibeam calls off pact to acquire Snapdeal unit Unicommerce. The firm is now evaluating options for an offshore listing.
Emcure is ranked among the top 15 pharmaceutical companies in India in terms of market share based on the domestic sales of pharmaceutical products. From Berlin to Washington: Will be displayed Will not be displayed Will be displayed.
Sensex finishes year above 36, posts third straight annual gain. Crude oil prices e,cure direct sugar prices in Promoter Satish Ramanlal Mehta holds This is the second exit by Blackstone from its India portfolio. Will the government be able to play This follows a deal struck late last year where Blackstone sold its stake to Bain Capital for an undisclosed amount.
Blackstone has exited now. Interestingly, all the firms which decided not to go ahead with public floats are backed by private equity investors.
Emcure Pharmaceuticals withdraws proposed IPO | VCCircle
Deepti Chaudhary Malvika Joshi. Blackstone has invested Rs crore in Emcure rdhp convertible shares and currently holds a The pharma company intends to utilise the net proceeds for setting up of new manufacturing facilities and expansion of existing manufacturing facilities; research and development; and general corporate purposes.
By Jasleen Kaur Batra. Emcure is a fast growing Indian pharmaceutical company engaged in developing, manufacturing and marketing a broad range of pharmaceutical products globally.
The company commercialises its products through a combination of its own marketing and distribution infrastructure. Choose your reason below and click on the Report button. Technicals Technical Chart Visualize Screener. For the nine months period ended December British support-services provider Serco Ejcure Plc.